Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.6MCash on Hand
7.4mo Cash Runway
Follow HYFT by emailGet an email when HYFT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HYFT, unsubscribe in one click. Privacy
📣 What HYFT Says Is Next
by 2027 · “By 2030, universal semantic layers will be treated as critical infrastructure alongside data platforms and cybersecurity; 44 percent of data and analytics leaders have implemented semantic layers and a further 48 percent plan to by 2027. gartner.com/en/newsroom Investor Relations Contact Louie Toma, CPA, CFA Managing Director, CoreIR investors@mindwalkai.com”
Company press release, Oct 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Financing MindWalk entered a definitive US$30 million senior unsecured revolving credit agreement with Sanabil (Cayman), dated November 16, 2026. The facility is undrawn at closing, bears 7.00% fixed on drawn amounts only, matures in 36 months, and has no financial covenants or equity component. Form 6-K · SEC filing · Press release
Nov 4, 2026 ·
Deal MindWalk announced a multi-year agreement with Teva Pharmaceuticals Australia to deploy its ReefIQ platform and specified LensAI capabilities in a defined scope of antibody-discovery work. Financial terms were not disclosed. Form 6-K · SEC filing · Press release
Oct 28, 2026 ·
Shareholder vote Notice of annual general meeting to be held via live webcast on November 17, 2026, at 10 a.m. (PST). Shareholders will receive fiscal year ended April 30, 2026 financial statements, elect directors, and appoint Davidson & Company LLP as auditors. Form 6-K · SEC filing · Press release
Oct 22, 2026 ·
Leadership MindWalk said Chief Business Officer Thomas Lynch departed effective October 16, 2026. CEO Jennifer Bath said commercial priorities are unchanged, with LensAI is in contracted, recurring deployments and the commercial team now reports to her. Form 6-K · SEC filing · Press release
Oct 21, 2026 ·
MindWalk reported a white paper showing its LensAI immunogenicity screening ran across 890,634 antibody sequences in 4 hours and 41 minutes on Amazon EC2 Hpc8a instances with AMD EPYC processors, at up to 43% lower cost per sequence than a comparable Intel configuration. Form 6-K · SEC filing · Press release
Oct 14, 2026 ·
Leadership MindWalk Holdings announced three senior hires in Boston to advance its pipeline toward preclinical efficacy studies: Zachary Maben, PhD, as Director of Antigen Discovery and Protein Engineering, Joanne Lim, PhD, as Director of Preclinical Development, and Shuji Sato, PhD, whose duties expand to include the pipeline. Form 6-K · SEC filing · Press release
Oct 6, 2026 ·
MindWalk issued a press release arguing that life sciences needs a biological context layer, promoting ReefIQ, its model-agnostic platform commercially available since June 2026. It reports no financial results, deal terms or offering amounts. Form 6-K · SEC filing · Press release
Oct 1, 2026 ·
Leadership MindWalk appointed Kim Remizowski as an independent director, effective September 29, 2026. He will serve on the Audit Committee and the Compensation, Nomination and Governance Committee. The Board now has four directors, three of them independent. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
HYFT holds $7.6M in cash and short-term investments and burns about $3.1M/quarter from operations,
an estimated runway of 7.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:40 · Elevated
Cash runway not available
ATM program on file since Jul 2026 +15
Shelf registration (F-3, Jul 2026) +10
Going-concern doubt in the latest 20-F +15We do not have sufficient cash reserves to fund our operations for the next twelve months, which raises substantial doubt about our ability to continue as a going concern.20-F, Jul 2026
Recent financing filings on SEC EDGAR:
Jul 13, 2026 · Shelf registration with ATM program, up to $30M · F-3
Share count 46,711,866 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full HYFT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HYFT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.